New antibody shows promise for blistering skin disease
NCT ID NCT04563923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested avdoralimab, an antibody that blocks a specific immune signal, added to standard steroid cream for bullous pemphigoid—a severe blistering skin condition mostly affecting older adults. Fifteen participants received the combination to see if it leads to complete remission faster than steroids alone. The study is small and early, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Avdoralimab (a monoclonal antibody) plus clobetasol propionate cream
What this could lead to
If it works, this could point toward a more targeted treatment for bullous pemphigoid that reduces reliance on steroids alone.
What could go wrong
This is a very small, early-phase trial with only 15 participants, so results may not apply broadly. The drug may not prove more effective than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM, Hôpital Nord
Marseille, Bouches du rhône, 13000, France
-
APHM, Timone
Marseille, Bouche Du Rhône, 13005, France
-
CHU Montpellier, Dermatologie
Montpellier, Herault, 34005, France
-
CHU de Nice- Dermatologie
Nice, Alpes-Maritimes, 06200, France